Sutro Biopharma ((STRO)) announced an update on their ongoing clinical study.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Sutro Biopharma’s recent clinical study update focuses on a Phase 1 trial of STRO-002, an anti-Folate Receptor Alpha (FolRα) antibody-drug conjugate, aimed at treating advanced epithelial ovarian and endometrial cancers. The study’s primary goal is to evaluate the safety, pharmacokinetics, and preliminary efficacy of STRO-002, which is significant for developing new treatments for these challenging cancers.
The intervention being tested is STRO-002, an intravenous antibody-drug conjugate designed to target and treat cancers expressing the FolRα protein, potentially offering a new therapeutic option for patients with limited treatment choices.
The study is an open-label, multicenter trial with a sequential intervention model, focusing on dose escalation and expansion to determine the maximum tolerated dose and recommended phase 2 dose. There is no masking involved, and the primary purpose is treatment.
The study began on February 1, 2019, with its primary completion date already reached. The last update was submitted on August 18, 2025, indicating ongoing analysis and data collection.
This study update could positively impact Sutro Biopharma’s stock performance and investor sentiment, as successful results may position the company as a leader in innovative cancer therapies. Competitors in the oncology space will be watching closely, as advancements here could shift market dynamics.
The study is ongoing, with further details available on the ClinicalTrials portal.